Literature DB >> 8435325

Clinical, haematological and cytogenetic features in 24 patients with structural rearrangements of the Q arm of chromosome 3.

A P Grigg1, R D Gascoyne, G L Phillips, D E Horsman.   

Abstract

To determine the frequency and clinical significance of acquired abnormalities of chromosome 3 at q21 and q25-26 in haematological malignancy, we reviewed the haematological and cytogenetic features of 24 patients with a 3q rearrangement identified amongst 1200 cases with clonal cytogenetic abnormalities detected at our institutions during a 12-year period. Thirteen patients presented with de novo acute myeloid leukaemia (AML), 10 with myelodysplasia (MDS) and one in blast phase of chronic myelogenous leukaemia. Twenty patients (83%) had megakaryocytic dysplasia and 14 (58%) had normal or increased numbers of megakaryocytes, but only four patients (16%) had absolute thrombocytosis > 500 x 10(9)/l (three with AML, one with MDS transforming to AML). A review of 205 cases of AML investigated in our institutions between 1985 and 1990 for whom cytogenetic results were obtained revealed that a platelet count > 500 x 10(9)/l at presentation was highly suggestive of an underlying 3q abnormality. A limited review of the literature on this subject confirmed that 15-20% of patients with a 3q abnormality will have thrombocytosis. The response of these patients to conventional antileukaemic therapy is uniformly poor, despite haematological and clinical differences between the subtypes of 3q rearrangements.

Entities:  

Mesh:

Year:  1993        PMID: 8435325     DOI: 10.1111/j.1365-2141.1993.tb04647.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  5 in total

1.  Biochemical detection of novel anaplastic lymphoma kinase proteins in tissue sections of anaplastic large cell lymphoma.

Authors:  K Pulford; B Falini; J Cordell; A Rosenwald; G Ott; H K Müller-Hermelink; K A MacLennan; L Lamant; A Carbone; E Campo; D Y Mason
Journal:  Am J Pathol       Date:  1999-06       Impact factor: 4.307

2.  Overexpression of EVI1 interferes with cytokinesis and leads to accumulation of cells with supernumerary centrosomes in G0/1 phase.

Authors:  Kadin Karakaya; Friederike Herbst; Claudia Ball; Hanno Glimm; Alwin Krämer; Harald Löffler
Journal:  Cell Cycle       Date:  2012-08-16       Impact factor: 4.534

Review 3.  Leukemogenesis of the EVI1/MEL1 gene family.

Authors:  Kazuhiro Morishita
Journal:  Int J Hematol       Date:  2007-05       Impact factor: 2.490

4.  Mutational spectrum of myeloid malignancies with inv(3)/t(3;3) reveals a predominant involvement of RAS/RTK signaling pathways.

Authors:  Stefan Gröschel; Mathijs A Sanders; Remco Hoogenboezem; Annelieke Zeilemaker; Marije Havermans; Claudia Erpelinck; Eric M J Bindels; H Berna Beverloo; Hartmut Döhner; Bob Löwenberg; Konstanze Döhner; Ruud Delwel; Peter J M Valk
Journal:  Blood       Date:  2014-11-07       Impact factor: 22.113

5.  EVI1 and GATA2 misexpression induced by inv(3)(q21q26) contribute to megakaryocyte-lineage skewing and leukemogenesis.

Authors:  Ayaka Yamaoka; Mikiko Suzuki; Saori Katayama; Daiki Orihara; James Douglas Engel; Masayuki Yamamoto
Journal:  Blood Adv       Date:  2020-04-28
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.